News Releases

Summary Toggle Teligent, Inc. Announces FDA Approval of Fluocinonide Topical Solution USP, 0.05%

BUENA, N.J. , March 19, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S.

March 19, 2019

PDF Version
Summary Toggle Teligent, Inc. Announces Fourth Quarter and Year End 2018 Results

BUENA, N.J. , March 18, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced its financial results for the fourth quarter and year ended December 31, 2018 . Fourth Quarter 2018 Highlights Net revenues of $16.8 million

March 18, 2019

PDF Version
Summary Toggle Teligent, Inc. to Present at the 31st Annual ROTH Conference Tuesday March 19, 2019

BUENA, N.J. , March 15, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at 31 st Annual ROTH Conference March 19, 2019 . The Conference is taking place March 17 th - March 19 th , 2019 at the Ritz Carlton Laguna

March 15, 2019

PDF Version
Summary Toggle Teligent, Inc. Announces FDA Approval of Desonide Ointment, 0.05%

BUENA, N.J. , March 14, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S.

March 14, 2019

PDF Version
Summary Toggle Teligent, Inc. to Hold Conference Call for Fourth Quarter 2018 Results

BUENA, N.J. , March 12, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, announced the Company will hold a conference call at 8:00am ET on Monday, March 18 th , 2019 to discuss the 4 th quarter 2018 financial results and business

March 12, 2019

PDF Version
Summary Toggle Teligent, Inc. to Present at The 8th Annual SVB Leerink Global Healthcare Conference Friday March 1, 2019

BUENA, N.J. , Feb. 27, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at The 8 th Annual SVB Leerink Global Healthcare Conference March 1, 2019 . The Conference is taking place February 27 th - March 1 st ,

February 27, 2019

PDF Version
Summary Toggle Teligent, Inc. Announces FDA Approval of Clobetasol Propionate Ointment USP, 0.05%

BUENA, N.J. , Jan. 24, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S.

January 24, 2019

PDF Version
Summary Toggle Teligent, Inc. Announces FDA Approval of Gentamicin Sulfate Ointment USP, 0.1%

BUENA, N.J. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S.

January 2, 2019

PDF Version
Summary Toggle Teligent, Inc. Executes $120 Million Financing Agreement

BUENA, N.J. , Dec. 13, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), (“Teligent” or the “Company”) announced today that on December 13, 2018 the Company entered into a definitive first lien revolving credit agreement with ACF Finco I LP , a limited partnership affiliated with Ares

December 13, 2018

PDF Version
Summary Toggle Teligent, Inc. Receives Notification of Deficiency From NASDAQ Related to the Delayed Filing of Form 10-Q

BUENA, N.J. , Nov. 16, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), on November 13, 2018 received a standard notice from NASDAQ stating that, as a result of not having timely filed its quarterly report on Form 10-Q for the quarterly period ended September 30, 2018 , Teligent is not in

November 16, 2018

PDF Version